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Systemic inflammation causes learning and memory
deficits through mechanisms that remain poorly
understood. Here, we studied the pathogenesis of
memory loss associated with inflammation and
found that we could reverse memory deficits by
pharmacologically inhibiting a5-subunit-containing
g-aminobutyric acid type A (a5GABAA) receptors
and deleting the gene associatedwith the a5 subunit.
Acute inflammation reduces long-term potentiation,
a synaptic correlate of memory, in hippocampal sli-
ces from wild-type mice, and this reduction was
reversed by inhibition of a5GABAA receptor function.
A tonic inhibitory current generated by a5GABAA
receptors in hippocampal neurons was increased
by the key proinflammatory cytokine interleukin-1b
through a p38 mitogen-activated protein kinase sig-
naling pathway. Interleukin-1b also increased the
surface expression of a5GABAA receptors in the
hippocampus. Collectively, these results show that
a5GABAA receptor activity increases during inflam-
mation and that this increase is critical for inflamma-
tion-induced memory deficits.
INTRODUCTION
Acute systemic inflammation caused by a variety of disorders,
including autoimmune diseases, infection, traumatic brain injury,
and stroke, can lead to memory loss (Dantzer et al., 2008; Di Fil-
ippo et al., 2008; Kipnis et al., 2008; Yirmiya and Goshen, 2011).
Such memory loss manifests as impaired explicit recall in hu-
mans, and deficiencies of fear-associated memory and reduced
performance for object-recognition tasks in laboratory animals
(Yirmiya and Goshen, 2011). Inflammation also contributes to
chronic neurodegenerative diseases that are characterized by488 Cell Reports 2, 488–496, September 27, 2012 ª2012 The Authormemory loss, including Alzheimer disease, Parkinson disease,
multiple sclerosis, and even AIDS-related dementia (Di Filippo
et al., 2008; Kipnis et al., 2008; Yirmiya and Goshen, 2011).
Systemic inflammation increases the production of multiple
cytokines in the brain, including interleukin-1b (IL-1b), tumor
necrosis factor-a (TNF-a), and IL-6 (Dantzer et al., 2008; Yirmiya
and Goshen, 2011). In particular, elevated levels of IL-1b are
known to contribute to inflammation-induced memory deficits.
For example, in patients with sepsis-associated encephalop-
athy, increased plasma levels of IL-1b were correlated with
cognitive deficits (Serantes et al., 2006). In another study, elderly
people with a genetic variant of the IL-1b-converting enzyme
that produces lower levels of IL-1b exhibited better cognitive
performance than the general aged population (Trompet et al.,
2008). In laboratory animals that underwent orthopedic surgery,
elevated levels of IL-1b in the hippocampus were strongly corre-
lated with memory deficits (Cibelli et al., 2010). Furthermore, it
was shown that memory deficits associated with elevated levels
of IL-1bwere typically hippocampus dependent, whereas hippo-
campus-independentmemory was spared (Yirmiya andGoshen,
2011).
The mechanisms underlying inflammation-induced memory
deficits are not well understood. Changes involving multiple
neurotransmitter receptors have been demonstrated, including
a reduction in N-methyl-D-aspartate (NMDA) receptor activity,
alterations in the trafficking and phosphorylation of 2-amino-3-
(5-methyl-3-oxo-1,2-oxazol-4-yl)propanoic acid receptors, and
activation of the a7 subtype of nicotinic acetylcholine receptors
(Stellwagen et al., 2005; Terrando et al., 2011; Viviani et al.,
2003). However, despite a long history of investigation, no treat-
ments that effectively reverse or prevent the memory deficits
associated with inflammation are available. General inhibition
of the inflammatory response and specific blocking of IL-1b
activity by inhibiting the membrane-bound type 1 IL-1 receptors
are impractical approaches because of the risks of infection
and delayed wound healing (Fleischmann et al., 2006). More-
over, low basal levels of IL-1b in the hippocampus play a physio-
logical role in maintaining normal memory performance (Yirmiyas
and Goshen, 2011). Thus, identification of additional down-
stream mediators of inflammation that induce memory loss is
necessary for the development of effective treatments.
The inhibitory neurotransmitter g-aminobutyric acid (GABA) is
a powerful regulator of learning, memory, and synaptic plasticity
(Collinson et al., 2002). GABA type A (GABAA) receptors generate
two distinct forms of inhibition: phasic, fast inhibitory postsyn-
aptic currents and a tonic form of inhibition that is primarily medi-
ated by extrasynaptic GABAA receptors (Brickley and Mody,
2012; Glykys and Mody, 2007; Luscher et al., 2011). In the CA1
subfield of the hippocampus, a tonic inhibitory conductance is
generated mainly by the a5-subunit-containing subtype of
GABAA (a5GABAA) receptors (Caraiscos et al., 2004), which are
likely composed of a5b3g2 subunits (Burgard et al., 1996; Glykys
and Mody, 2007; Ju et al., 2009). Drugs that increase a5GABAA
receptor activity cause profound memory blockade (Cheng
et al., 2006; Martin et al., 2009). Conversely, a reduction in the
expression or function of this receptor improves performance
for certain memory tasks (Collinson et al., 2002; Martin et al.,
2010). Here, using a combination of behavioral studies, electro-
physiological recordings, and biochemical methods together
with genetic and pharmacological tools, we sought to determine
whether increased a5GABAA receptor activity contributes to
inflammation-induced memory deficits. The results of these
studies show that a5GABAA receptors are critical downstream
mediators of inflammation-induced memory deficits.
RESULTS
a5GABAA Receptors Regulate Inflammation-Induced
Impairment of Contextual Fear Memory
We first investigated the role of a5GABAA receptors in inflamma-
tion-induced deficits using a fear-associated memory paradigm
(Fanselow and Poulos, 2005). Wild-type (WT) and a5-subunit null
mutant (Gabra5/) micewere treatedwith IL-1b (1 mg kg1, i.p.)
to mimic acute systemic inflammation (Yirmiya and Goshen,
2011). Three hours after treatment, the mice were trained to
associate an electric foot shock (unconditioned stimulus) with
an environmental context and a tone (conditioned stimuli). To
study contextual fear memory, which is hippocampus depen-
dent (Fanselow and Poulos, 2005), we reexposed the mice to
the same environmental context 24 hr after training. To study
cued fear memory in response to tone, which is hippocampus
independent (Fanselow and Poulos, 2005), we reexposed the
mice to the tone after training. The percentage of time that
each mouse spent freezing in the same context or in response
to the tone was used to assess memory. IL-1b-treated WT
mice showed impairment of contextual fear memory, as evi-
denced by lower freezing scores compared with vehicle-treated
controls (Figure 1A; n = 14–16; two-way analysis of variance
[ANOVA], effect of IL-1b, F(1,56) = 5.60, p = 0.02; effect of geno-
type, F(1,56) = 0.07, p = 0.79; effect of interaction, F(1,56) = 2.86,
p = 0.10; Bonferroni post hoc test, p < 0.05), as shown previously
(Yirmiya and Goshen, 2011). In contrast, Gabra5/ mice
treated with IL-1b exhibited no memory deficits (Figure 1A; n =
14–16; Bonferroni post hoc test, p > 0.05).
To determine whether pharmacological inhibition of a5GABAA
receptors would prevent the memory deficit, we studied theCeleffects of two benzodiazepine inverse agonists that pref-
erentially inhibit a5GABAA receptors (Atack et al., 2009; Quirk
et al., 1996). At 30 min before fear conditioning, the mice
were treated with either L-655,708 [ethyl (13aS)-7-methoxy-
9-oxo-11,12,13,13a-tetrahydro-9H-imidazo[1,5-a]pyrrolo[2,1-c]
[1,4]benzodiazepine-1-carboxylate] (0.35 or 0.5 mg kg1, i.p.)
or MRK-016 [3-tert-butyl-7-(5-methylisoxazol-3-yl)-2-(1-methyl-
1H-1,2,4-triazol-5-ylmethoxy)-pyrazolo[1,5-d][1,2,4]triazine]
(3 mg kg1, i.p.). Of note, under baseline conditions, L-655,708
does not modify contextual fear memory in WT or Gabra5/
mice (Martin et al., 2010). However, L-655,708 reversed the
contextual fearmemorydeficits inducedby IL-1b inWTmice (Fig-
ure 1B; n= 11; Student’s t test, t=2.0, p= 0.03). Similarly, another
inverse agonist that is structurally distinct from L-655,708, MRK-
016, attenuated the contextual fear memory deficits induced
by IL-1b in WT mice (Figure 1B; n = 16; Student’s t test, t = 2.1,
p = 0.04).
We next used awidely employedmodel of systemic inflamma-
tion to probe whether elevated levels of endogenous cytokines
also impair memory through activation of a5GABAA receptors.
WT and Gabra5/ mice were treated with the gram-negative
bacterial endotoxin lipopolysaccharide (LPS; 125 mg kg1, i.p.)
3 hr before behavioral training. WT mice, but not Gabra5/
mice, exhibited a reduction in contextual fearmemory after treat-
ment with LPS (Figure 1C; n = 10–15; two-way ANOVA, effect of
LPS, F(1,53) = 8.16, p = 0.006; effect of genotype, F(1,53) = 0.0005,
p = 0.98; effect of interaction, F(1,53) = 1.02, p = 0.32; Bonferroni
post hoc test, p < 0.05 for WT). The deficit exhibited by WT mice
was reversed by inhibiting a5GABAA receptors with L-655,708
(Figure 1C; n = 10–11; Student’s t test, t = 2.7, p = 0.01).
Of interest, treatment with either IL-1b or LPS did not affect
cued fear memory in response to the conditioned tone (Figures
1D and S1; n = 14–16; two-way ANOVA, effect of IL-1b,
F(1,54) = 1.28, p = 0.26; effect of genotype, F(1,54) = 1.45, p =
0.23; effect of interaction, F(1,54) = 0.06, p = 0.80). Collectively,
these results suggest that the impairment of memory induced
by inflammation did not result from a global disruption of cogni-
tive processes, but rather from disruption of hippocampal
function.
a5GABAA Receptors Regulate Inflammation-Induced
Impairment of Long-Term Potentiation
Long-term potentiation (LTP), which refers to the prolonged
enhancement of excitatory synaptic transmission, is a widely
studied cellular model of learning and memory (Lynch, 2004).
We next examined whether the activity of a5GABAA receptors
regulates the impairment of LTP induced by acute inflammation.
Brain slices were prepared from mice 3 hr after they were in-
jected with the endotoxin LPS (125 mg kg1, i.p.). Theta burst
stimulation of the Schaffer collateral pathwaywas used to induce
LTP in the CA1 subfield of the hippocampus, and field postsyn-
aptic potentials (fPSPs) were recorded before and after stimula-
tion (Figure 2A, inset). In slices from the vehicle-treatedWTmice,
after stimulation, the slope of the fPSPs increased to 136.1% ±
5.6% of baseline (n = 9). In contrast, in slices from the LPS-
treated mice, the increase in LTP was only 113.1% ± 2.5% of
baseline (n = 10; one-way ANOVA, F(2,26) = 4.38, p = 0.02; New-
man-Keuls post hoc test, p < 0.05; Figures 2A and 2B).l Reports 2, 488–496, September 27, 2012 ª2012 The Authors 489
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Figure 1. Inflammation-Induced Impairment of Contextual Fear Memory Is Absent in Gabra5/ Mice and Can Be Prevented by Pharma-
cological Inhibition of a5GABAA Receptor in WT Mice
(A) IL-1b reduced the freezing scores for contextual fear memory only in WT mice. The bar graph shows the summarized results.
(B) L-655,708 or MRK-016 restored the freezing scores for contextual fear memory to control values in WT mice.
(C) LPS reduced the freezing scores for contextual fear memory only in WT mice, and L-655,708 restored the freezing scores to control values in WT mice.
(D) IL-1b did not affect the freezing scores for cued fear memory in response to tone in bothWT andGabra5/mice. Data are represented asmean ± SEM. Here
and in subsequent figures, Con stands for control. *p < 0.05, **p < 0.01, ***p < 0.001, N.S.: nonsignificant result.
See also Figure S1.
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Figure 2. Inflammation Attenuates LTP in CA1 Region Only in WT
Mice and This Can Be Prevented by Pharmacological Inhibition of
a5GABAA Receptor
(A) LPS impaired LTP induced by theta burst stimulation only in slices fromWT
mice. See also Figure S2.
(B) Summarized data showing the last 5 min of the recording. Note that
pharmacological inhibition of a5GABAA receptors with L-655,708 prevented
the impairment of LTP by LPS. Perfusion of the slices with L-655,708 (20 nM)
was started 10 min before the stimulation and was present for LTP recording.
Data are represented as mean ± SEM.Pharmacological inhibition of a5GABAA receptors in hippo-
campal slices by application of L-655,708 (20 nM) eliminated
LPS-induced reduction of LTP (fPSP slope: 130.3% ± 7.7% of
baseline, n = 10; one-way ANOVA followed by Newman-KeulsCelpost hoc test, p < 0.05; Figure 2B). Furthermore, in slices from
Gabra5/ mice, LPS failed to impair LTP. The fPSP slope
was 133.1% ± 4.3% of baseline for LPS treatment (n = 15)
compared with 135.4% ± 5.9% of baseline for vehicle treatment
(n = 13; Figures 2A and 2B), and there was no significant differ-
ence compared with the WT (two-way ANOVA, effect of LPS,
F(1,43) = 6.33, p = 0.02; effect of genotype, F(1,43) = 3.71, p =
0.06; effect of interaction, F(1,43) = 4.28, p = 0.04; Bonferroni
post hoc test, p > 0.05 for Gabra5/). Together, these results
suggest that a5GABAA receptors are required for inflamma-
tion-induced impairment of LTP.
Next, to determine whether the LPS-induced reduction in LTP
was mediated in part by IL-1b binding to the IL-1 receptor, as
was suggested previously (Lynch et al., 2004), slices from LPS-
treated mice were incubated with the specific IL-1 receptor
antagonist (IL-1ra; 100 ng ml1 for 1 hr before recording). IL-
1ra restored LTP to 126.2% ± 3.9% of baseline (n = 10; p <
0.05 compared with LPS; Figure S2), which confirmed that the
reduction in LTP was largely mediated by an increase in IL-1b
activity.
IL-1b Increases the Tonic Current in the CA1 region
In the CA1 region of the hippocampus, a tonic inhibitory conduc-
tance generated by a5GABAA receptors regulates synaptic plas-
ticity andmemory processes (Collinson et al., 2002; Martin et al.,
2010), and an increase in the activity of these receptors causes
memory deficits (Cheng et al., 2006; Martin et al., 2009). There-
fore, we next determined whether IL-1b increases the amplitude
of the tonic inhibitory current in CA1 pyramidal neurons by
recording whole-cell currents in brain slices from WT mice in-
jected with IL-1b (1 mg kg1, i.p., 2–3 hr before sacrifice) or
vehicle control (0.1% bovine serum albumin in phosphate-
buffered saline). To investigate the changes in tonic current,
the GABAA receptor antagonist bicuculline (Bic; 10 mM) or
L-655,708 (20 nM) was applied, and the reduction in holding
current was measured (Caraiscos et al., 2004; Glykys and
Mody, 2007). In slices from IL-1b-treated mice, a 2-fold increase
in tonic current density revealed by either Bic or L-655,708 was
observed relative to vehicle-treated controls (Student’s t test,
n = 11–14, t = 2.2, p = 0.04 for Bic; n = 6–10, t = 2.3, p = 0.04
for L-655,708; Figure 3A).
IL-1b Increases a5GABAA Receptor Activity in Cultured
Neurons
To investigate whether IL-1b directly enhances the tonic inhibi-
tory conductance, whole-cell currents were recorded from
cultured hippocampal neurons. The cell culture preparation
offers the advantage of a high-throughput assay that can be
used to study the effects of proinflammatory cytokines on the
tonic and synaptic inhibitory currents. Treatment of the neurons
with IL-1b (20 ng ml1 for 20 min) increased the amplitude of the
tonic current by 45% (IL-1b 1.6 ± 0.1 pA pF1, n = 22, versus
control 1.1 ± 0.1 pA pF1, n = 21; one-way ANOVA, F(4,80) =
7.13, p < 0.0001; Dunnett’s post hoc test, p < 0.001 compared
with control; Figure 3B). Increasing the concentration and dura-
tion of IL-1b treatment (60 ng ml1 for 3 h) further increased the
current amplitude (IL-1b 2.0 ± 0.3 pA pF1, n = 6, versus control
1.2 ± 0.2 pA pF1, n = 6; Student’s t test, t = 2.21, p = 0.03). Nol Reports 2, 488–496, September 27, 2012 ª2012 The Authors 491
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Figure 3. IL-1b Increases the Tonic Current
(A) The toniccurrentdensity revealedbyBic (10mM)
and L-655,708 (20 nM) was increased 2-fold in
slices from mice treated with IL-1b (1.0 mg kg1)
compared with vehicle-treated controls.
(B–G) IL-1b increased the tonic current generated
by a5GABAA receptors in cultured hippocampal
neurons.
(B) Exogenous IL-1b (20 min) increased the tonic
current, as revealed by the application of Bic
(100 mM, left). The concentration-dependent
effects of IL-1b on tonic current density are shown
on the right (n = 13–22).
(C) IL-1b enhancement of tonic current was
blocked by coapplication of IL-1ra (250 ng ml1,
30 min).
(D) A representative recording showing the tonic
currents revealed by Bic (100 mM) or by the in-
verse agonist for a5GABAA receptors, L-655,708
(20 nM).
(E and F) a5GABAA receptors are necessary for
the enhancing effects of IL-1b on the tonic current
revealed by (E) Bic (100 mM) and (F) L-655,708
(20 nM); n = 7–13; two-way ANOVA. (E) Effect of
IL-1b: F(1,37) = 9.19, p = 0.004; effect of genotype:
F(1,37) = 31.14, p < 0.0001; effect of interaction:
F(1,37) = 4.35, p = 0.04. (F) Effect of IL-1b: F(1,36) =
8.17, p = 0.007; effect of genotype: F(1,36) =
138.92, p < 0.0001; effect of interaction:
F(1,36) = 10.43, p = 0.03. Bonferroni post hoc test,
**p < 0.01, ***p < 0.001 compared with control.
(G) The tonic current was increased by treating
neuron and microglia cocultures, but not neurons
cultured alone, with LPS (100 ng ml1, overnight).
The LPS-enhancing effects on the tonic current
were blocked by treating the cocultures with IL-
1ra (250 ng ml1, overnight). Data are represented
as mean ± SEM.
See also Figure S3 and Table S1.further increase in current amplitude was observed when
neurons were treated for 12–15 hr (IL-1b 20 ng ml1 1.3 ±
0.6 pA pF1, n = 21, versus control 0.8 ± 0.08 pA pF1, n = 12;
Student’s t test, t = 4.05, p = 0.0003). This concentration-depen-
dent increase in tonic current by IL-1b was completely blocked492 Cell Reports 2, 488–496, September 27, 2012 ª2012 The Authorsby IL-1ra (250 ng ml1 for 30 min, n =
11–22; one-way ANOVA, F(3,61) = 7.92,
p = 0.0002; Dunnett’s post hoc test, p <
0.001 compared with control; Figure 3C).
Because acute inflammation is as-
sociated with increased levels of other
key cytokines, including TNF-a and IL-6
(Dantzer et al., 2008; Yirmiya andGoshen,
2011), we examined the effects of
these cytokines on the tonic current. No
changes in the tonic current were ob-
served when neurons were treated for
20 min with TNF-a (100 ng ml1 0.9 ±
0.08 pA pF1, 500 ng ml1 1.0 ± 0.1 pA
pF1, versus control 1.0 ± 0.06 pA pF1,
n = 10–14; one-way ANOVA, F(2,34) =0.05, p = 0.95) or IL-6 (10 ng ml1 0.9 ± 0.05 pA pF1, versus
control 1.0 ± 0.06 pA pF1, n = 5; Student’s t test, t = 0.50,
p = 0.63).
Neurons in the hippocampus express a variety of GABAA
receptor subtypes (Glykys and Mody, 2007; Luscher et al.,
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Figure 4. Mechanisms for IL-1b-Induced
Enhancement of the Tonic Current
(A) Treatment with an inhibitor of p38 MAPK,
SB203,580 (p38 Anta, 20 mM, 30 min) abolished
the effect of IL-1b (20 ng ml1, 20 min) on the tonic
current (left). SB202,474 (SB202, 10 mM, 30 min),
an inactive analog of the p38 MAPK inhibitor
SB203,580, did not block the enhancing effects of
IL-1b on the tonic current (right).
(B and C) IL-1b-induced enhancement of the tonic
current was not blocked by the JNK antagonist
SP600,125 (JNK Anta, 1 mM, 30 min) or the PI3K
antagonist LY294,002 (PI3K Anta, 20 mM, 30 min).
(B) n = 11–16; one-way ANOVA, F(2,37) = 14.42,
p < 0.0001. (C) n = 10–12; one-way ANOVA,
F(2,30) = 11.13, p = 0.0002. Dunnett’s post hoc
test, ***p < 0.001 compared with control.
(D) The surface expression of the a5 subunit in
hippocampal slices treated with IL-1b (20 ng ml1,
40 min) was increased compared with vehicle-
treated control slices. Data are represented as
mean ± SEM.
See also Figure S4.2011). To further examine whether the IL-1b-enhanced tonic
current was indeed mediated by a5GABAA receptors, we used
a combination of pharmacological and genetic approaches.
We first studied the effects of L-655,708 (20 nM), which inhibited
the tonic current in WT neurons by 56.6% ± 9.2% (n = 7; Fig-
ure 3D). This effect size is consistent with the efficacy of
L-655,708 for inhibition of a5GABAA receptors (Quirk et al.,
1996). Next, we found that IL-1b increased the tonic current re-
vealed by both Bic and L-655,708 recorded in WT neurons, but
did not increase the tonic current recorded in Gabra5/
neurons (Figures 3E and 3F). These results suggest that the
a5GABAA receptors are necessary for IL-1b enhancement of
the tonic current.
We next studied whether elevated levels of endogenous IL-1b
also enhance the tonic current. Cocultures of microglia and
neurons were prepared and treated with the endotoxin LPS
(100 ng ml1 for 12–15 h) to stimulate release of IL-1b, as previ-
ously described (Polazzi and Contestabile, 2006). LPS treatment
increased the tonic current, an effect that was fully reversed by
treating the cocultures with IL-1ra (250 ng ml1, n = 13–19;
one-way ANOVA, F(3,62) = 7.27, p = 0.0003; Newman-Keuls
post hoc test, ** p < 0.01, *** p < 0.001 compared with LPS; Fig-
ure 3G). However, the tonic current studied in neurons that were
cultured alone, in the absence of microglia, was unchanged by
LPS (n = 10–14; Student’s t test, t = 0.10, p = 0.92; Figure 3G),
which suggests that IL-1bwas released from activated microglia
in the cocultures (Polazzi and Contestabile, 2006).
In the hippocampus, GABAA receptors also generate fast tran-
sient inhibitory postsynaptic currents that are predominantlyCell Reports 2, 488–496, Semediated by GABAA receptors lacking
the a5 subunit (Glykys and Mody, 2007).
To determine whether IL-1b also en-
hances synaptic inhibition, we recorded
miniature inhibitory postsynaptic currents
(mIPSCs) from cultured hippocampalneurons. IL-1b caused a modest reduction in the mIPSCs (Fig-
ure S3; Table S1). Collectively, these results suggest that IL-1b
preferentially increases the activity of GABAA receptors that
generate tonic (but not synaptic) currents.
IL-1b Increases the Tonic Current via the p38 Mitogen-
Activated Protein Kinase-Dependent Pathway
Next, to identify the predominant signaling pathways by which
IL-1b increases the tonic currents, we treated hippocampal
neurons with selective kinase inhibitors. SB203,580, an inhibitor
of p38 mitogen-activated protein kinase (MAPK), completely
blocked the IL-1b-induced increase in the tonic current (n =
10–14; one-way ANOVA, F(3,45) = 4.85, p = 0.005; Dunnett’s
post hoc test, p < 0.05 compared with control; Figure 4A),
whereas its inactive analog, SB202,474 had no effect (n =
9–11; one-way ANOVA, F(3,35) = 11.10, p < 0.0001; Dunnett’s
post hoc test, ** p < 0.01 *** p < 0.001 compared with control;
Figure 4A). This result suggested that p38 MAPK mediates the
IL-1b-induced increase in tonic current. Inhibitors of c-Jun
N-terminal kinases (JNKs; SP600,125) and phosphatidylinositol
3-kinases (PI3Ks; LY294,002) had no effect on IL-1b enhance-
ment of the tonic current, showing that activation of these
kinases was not required (Figures 4B and 4C).
MAPK signaling pathways are important regulators of GABAA
receptor trafficking (Luscher et al., 2011). Thus, we studied
whether IL-1b increased the expression of a5GABAA receptors
on the surface of neurons. Hippocampal slices were treated
with IL-1b (20 ng ml1 for 40 min), and a quantitative western
blot analysis of the biotinylated proteinwas performed (Abramianptember 27, 2012 ª2012 The Authors 493
et al., 2010). The surface expression of the a5-subunit protein
in IL-1b-treated slices was increased to 157.4% ± 17.6% of
the surface protein measured in vehicle-treated control slices
(n = 6, one-sample t test, t = 3.27, p = 0.02; Figure 4D). The
surface expression of the a1 and a2 subunits was also studied,
because these subunits are widely expressed and contribute
primarily to synaptic GABAA receptors (Glykys and Mody,
2007; Luscher et al., 2011). IL-1b decreased the surface expres-
sion of thea1 subunit but did notmodify the surface expression of
the a2 subunit (Figure S4). These results are consistent with the
observation that IL-1b caused a modest decrease in the ampli-
tude of postsynaptic currents.
DISCUSSION
The results described here show that inflammation causes
memory loss, at least in part, by increasing a tonic inhibitory
conductance that is generated by a5GABAA receptors. We
observed that genetic or pharmacological inhibition of a5GABAA
receptors was sufficient to prevent impairment of contextual fear
memory and synaptic plasticity induced by LPS and IL-1b.
Further, IL-1b increased the tonic conductance generated by
a5GABAA receptors in hippocampal neurons via activation of
IL-1 receptors and p38 MAPK-dependent signaling. This in-
creased tonic conductance by IL-1b was most likely due to an
increase in the surface expression of a5GABAA receptors.
Multiple signaling pathways are activated by IL-1b binding
to the IL-1 receptor, including pathways involving p38
MAPK, JNKs, and PI3Ks (O’Neill, 2002). Our results show that
IL-1b enhances the tonic inhibitory conductance mediated by
a5GABAA receptors primarily via activation of the p38 MAPK-
dependent pathway. Activation of p38 MAPK by IL-1b has
been shown in hippocampal neurons (Srinivasan et al., 2004)
and cortical neurons (Li et al., 2003). Also, consistent with our
results, others have shown that activation of p38 MAPK medi-
ates the effects of IL-1b on hippocampal LTP (Coogan et al.,
1999; Kelly et al., 2003).
The increase in tonic current was accompanied by an increase
in the surface expression of a5GABAA receptors. Membrane
clustering of a5GABAA receptors depends on the presence of
radixin, an actin-binding protein that anchors the a5 subunit to
cytoskeletal elements (Loebrich et al., 2006). Radixin is targeted
by p38 MAPK (Koss et al., 2006), and phosphorylation of radixin
could lead to enhanced membrane stability and clustering of
a5GABAA receptors at extracellular sites. Alternatively, IL-
1b-dependent activation of p38 MAPK could lead to increased
activity of downstream mediators such as cAMP response
element-binding protein (Srinivasan et al., 2004), which may
also enhance the surface expression of a5GABAA receptors.
The available evidence indicates that IL-1b increases the tonic
current primarily by increasing the expression of receptors on the
surface rather than causing an increase in the concentration of
agonist. Specifically, we studied the tonic current in cultured
neurons and slices under ‘‘concentration-clamp’’ conditions, in
which the extracellular concentration of GABA was fixed. Under
these conditions, IL-1b increased the amplitude of the tonic
current. Nevertheless, it is plausible that IL-1b also causes a
concurrent increase in ambient levels of GABA in the brain in494 Cell Reports 2, 488–496, September 27, 2012 ª2012 The Authoraddition to increasing the surface expression of a5GABAA
receptors. The concentration of GABA in the extracellular
space increases in many proinflammatory states, such as stress
(de Groote and Linthorst, 2007), stroke (Clarkson et al., 2010),
and pain (Kupers et al., 2009). The increase in extracellular
GABA could result from enhanced transmitter release and/or
decreased reuptake of GABA. It is unlikely that such an increase
in GABA induced by IL-1b is due to synaptic vesicular release,
because the frequency of mIPSCs was not increased in the
current study. Instead, reduced reuptake via GABA transporters
(Wu et al., 2007), as well as increased release of GABA from acti-
vated glial cells (Lee et al., 2010), may increase GABA levels in
the brain.
It is of interest that inflammation impairs memory performance
in response to context but not to tone, because the former (but
not the latter) behavior depends on the hippocampus (Fanselow
and Poulos, 2005). This result is consistent with the relatively
restricted expression of a5GABAA receptors to the hippo-
campus (Pirker et al., 2000). In the hippocampus, d-subunit-con-
taining GABAA (dGABAA) receptors are also located in extrasy-
naptic regions of the neurons, where they generate a tonic
inhibitory conductance (Glykys and Mody, 2007). Our results
do not rule out the possibility that inflammation modifies other
GABAA receptor subtypes, including dGABAA receptors; how-
ever, these other subtypes are unlikely to play a role in memory
loss. Gabra5/ mice express dGABAA receptors, yet IL-1b
failed to increase the tonic current in the hippocampal neurons
of thesemice. Also, inflammation did not inducememory deficits
in Gabra5/ mice. Of note, inflammation impairs synaptic
plasticity in the dentate gyrus region, where the expression of
a5GABAA receptors is low under baseline conditions (Glykys
and Mody, 2007; Kelly et al., 2003). The levels of a5GABAA
receptors in the dentate gyrus could be increased during
inflammation. In support of this notion, the activity of a5GABAA
receptors increases in the frontal cortex after ischemic stroke
(Clarkson et al., 2010).
The current study has several limitations. The first of these
relates to the widely used model that we employed to induce
systemic inflammation via intraperitoneal injection of IL-1b and
LPS. This experimental model mimics many of the features of
acute systemic illness in humans (Yirmiya and Goshen, 2011);
however, the method does not restrict the induction of inflam-
mation to the hippocampus. Second, the Gabra5/ mouse
does not limit the reduction of expression either regionally or
temporally. Also, global deletion of genes for GABAA receptor
subunits can lead to compensatory changes in the expression
of other subunits or proteins, although this has not been
reported for Gabra5/ mice (Collinson et al., 2002; Crestani
et al., 2002). Behaviors elicited by pharmacological treatments
with L-655,708 and MRK-016 faithfully mimicked behaviors ex-
hibited by Gabra5/ mice. Future studies employing condi-
tional mutagenesis of the Gabra5 gene that is restricted to the
CA1 subfield would advance our understanding of the specific
role of a5GABAA receptors in the CA1 hippocampus. Finally,
although the consequences of injecting various drugs directly
into the hippocampus would be of interest, we did not perform
such experiments, in part because of the requirement for care-
fully designed and performed control experiments, given thats
inflammation induced by surgery (Cibelli et al., 2010) and treat-
ment with general anesthetics (Zurek et al., 2012) can cause
long-term impairment of memory performance.
Currently, no treatments are available to reduce the memory
deficits associated with inflammation. The results of this study
indicate that the attenuation of memory loss by the administra-
tion of inverse agonists for a5GABAA receptors is a potential
treatment strategy. Because of the restricted expression of
a5GABAA receptors in the hippocampus (Pirker et al., 2000),
the inverse agonists that inhibit these receptors are generally
well tolerated and lack the proconvulsant and anxiogenic prop-
erties of nonselective GABAA receptor antagonists (Atack,
2010). Finally, this study may stimulate interest in the effects of
inflammation on GABAA receptors that are expressed in tissues
outside the nervous system (Watanabe et al., 2002), including
the lung and liver. Upregulation of these GABAA receptors may
also contribute to organ dysfunction associated with infection,
trauma, and immune-related diseases (Dantzer et al., 2008).
EXPERIMENTAL PROCEDURES
All experimental procedures were approved by the Animal Care Committee of
the University of Toronto (Toronto, ON, Canada). In all studies, the experi-
menter was blinded to the drug treatment and genotype of the mice. For
behavioral analysis and studies of hippocampal plasticity, male 3- to 4-
month-old WT and Gabra5/ mice were used. Experiments were started
3 hr after injection of IL-1b (1 mg kg1, i.p.) or LPS (125 mg kg1, i.p.) because
cytokine levels, and particularly IL-1b peak at this time point (Hansen et al.,
2000; Yirmiya and Goshen, 2011). Pavlovian fear conditioning was used to
study memory performance. Eachmouse was trained to associate the context
and a 3,600 Hz tone lasting 20 s with an electric foot shock (2 s, 0.5 mA). Each
sequence was presented three times, separated by 60 s. LTP was induced in
the hippocampal slices with a theta burst stimulation, which consisted of 10
stimulus trains at 5 Hz, with each train consisting of four pulses at 100 Hz.
Whole-cell voltage-clamp recordings were obtained from hippocampal slices,
cell culture, and neuron-microglia coculture. To record the tonic GABAergic
current, 5 or 0.5 mM GABA was added to the slices or cultured neurons,
respectively. All recordings were performed at a holding potential of
60 mV. A cell-surface biotinylation assay was used to determine the surface
expression of GABAA receptor a1, a2, and a5 subunits. Data are represented
as themean ±SEM. A Student’s paired or unpaired t test was used to compare
pairs of data. To compare three or more groups, a one-way (drug treatment
only) or two-way (drug treatment versus genotype) ANOVA followed by a Dun-
nett, Newman-Keuls, or Bonferroni post hoc test was used. A one-sample t
test was used to compare the surface expression of GABAA receptor subunits.
Statistical significance was set at p < 0.05.
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